Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (age ≥18 years), male or female.~* American Society of Anesthesiology (ASA) status I to III.~* Able to read and understand the information sheet~* Subjects who have signed and dated the consent form.~* Scheduled for elective surgery.~* If the patient is female and of childbearing potential, she must have a negative pregnancy test (serum hCG or urine dipstick).~Exclusion criteria:~* A history of allergy or hypersensitivity to dexamethasone or any component of its formulation.~* Hepatic dysfunction\* (i.e bilirubin \<1.5 upper limit normal (ULN), alanine aminotransferase (ALT) \<2.5 x ULN, aspartate aminotransferase (AST) \<2.5 x ULN).~* Renal insufficiency\* (i.e. creatinine \<1.5 x ULN, creatinine clearance \<30ml min-1).~* Pregnant, or intending to become pregnant, women.~* Breastfeeding women.~* Patient having used any investigational drug within 30 days of screening.~* Patient having participated in any clinical trial within 30 days.~* Patients with active GI ulcer.~* Patients needing prolonged postoperative intubation.~* Patients needing a gastric tube postoperatively.~* Patients receiving antiemetic drugs (butyrophenones, 5-HT3 receptor antagonists, dexamethasone).~* Patients taking drugs that interfere with platelet aggregation (for instance, aspirine or clopidogrel) within seven days preoperatively.~* Patients with overt psychosis or taking antipsychotic treatment (for instance, anti-dopaminergic drugs).~* Patients taking drugs with known emetogenic potency (for instance, L-Dopa, COMT inhibitors).~* Specific types of surgery: tonsillectomy (increased risk of postoperative bleeding), interventions that require strict prevention of postoperative vomiting.~* Systemic infections (bacterial, fungal, malaria, viral, tuberculosis).~* Local infections (for instance, ocular herpes simplex).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Injection of Placebo (Type: PLACEBO_COMPARATOR): Intravenous Saline 0.9% 10 ml
- Dexamethasone 3 mg (Type: ACTIVE_COMPARATOR): Intravenous Dexamethasone 3mg diluted in saline 0.9% up to 10 ml
- Dexamethasone 6 mg (Type: ACTIVE_COMPARATOR): Intravenous Dexamethasone 6mg diluted in saline 0.9% up to 10 ml
- Dexamethasone 12 mg (Type: ACTIVE_COMPARATOR): Intravenous Dexamethasone 12mg diluted in saline 0.9% up to 10 ml

Based on this trial design, predict the completion outcome and termination type (if applicable).